Press Release

Apopgenix to Present Positive Phase II Results of APG101 in Glioblastoma Multiforme at ASCO

- Primary study endpoint of increasing percentage of patients reaching PFS6 by 100% was exceeded by a factor of five

Heidelberg, Germany, May 29, 2012 - The biopharmaceutical company Apogenix GmbH announced today that results of the recently completed phase II clinical efficacy trial with APG101 for the treatment of Glioblastoma Multiforme (GBM) will be presented at the world's largest oncology congress ASCO – the Annual Meeting of the American Society of Clinical Oncology - in Chicago on June 1, 2012. An oral presentation of the data will be held on Friday, June 1 2012, at 4.30 pm local time (CDT).

In this comparative, randomized, open-label trial, patients were treated with either a combination of APG101 and radiotherapy or with radiotherapy alone. The primary endpoint was progression-free survival at six months (PFS6). In the APG101 study arm, the proportion of GBM patients who survived progression free for more than six months, improved by five times compared to the comparison group.

The phase II clinical trial recruited 83 patients in 27 centers throughout Germany, Austria, and Russia. Patients were eligible for inclusion if they had suffered from first or second relapses and if they no longer responded to treatment with Temozolomide. GBM patients participated in this study until tumor progression. Currently, there are no approved treatment options for second line GBM patients with proven efficacy data from an actively controlled study.

GBM is the most frequent and aggressive brain tumor type. The tumors are characterized by a high resistance to radiotherapy and chemotherapy. The disease often has a devastating impact on the quality of life and life expectancy of patients. Approximately 28,000 new cases of malignant glioblastomas are diagnosed in the US and EU each year.

Information regarding the poster presentation:

Abstract-Nr.: 2034
Abstract Title: APG101_CD_002: A phase II, randomized, open-label, multicenter study of weekly APG101 plus reirradiation versus reirradiation in the treatment of patients with recurrent glioblastoma.
Time and place of presentation: Friday, June 1st 2012, 1.00 - 5.00 pm Chicago local time (CDT), oral presentation at 4.30 pm local time (CDT)
Poster-Session: General Poster Session: Central Nervous System Tumors
Authors: M. Bendszus, J. Debus, W. Wick, G. Kobyakov, T. Martens, O. Heese, J. Pichler, R. Stupp, C. Kunz, H. Fricke;
The Abstract is available at the ASCO website under the following link: http://abstract.asco.org/AbstView_114_97870.html.
About Apogenix
Apogenix, a spin-out from the German Cancer Research Center (DKFZ), is developing novel protein therapeutics for the treatment of cancer and inflammatory diseases based either on the targeted modulation of apoptosis (programmed cell death) or on blocking the growth of tumor cells. The company’s lead product candidate APG101 is being developed for the treatment of Glioblastoma Multiforme (GBM), the most common and aggressive type of primary brain tumor. In 2013, it is planned to initiate a phase II trial with APG101 for the treatment of Myelodysplastic Syndromes (MDS). Since its inception in 2005, the company has raised more than €50 million with dievini Hopp BioTech Holding GmbH & Co. KG as main investor, and has been awarded public grants totaling over €8 million. Apogenix is based in Heidelberg, Germany.

About APG101
The company’s lead product candidate, APG101, a first-in-class, fully human fusion protein combining the extracellular domain of the CD95 receptor and the Fc portion of IgG, successfully completed a phase I study in 2009. In December 2009, Apogenix started a controlled phase II trial with APG101 for the treatment of Glioblastoma Multiforme. The patient recruitment for this study was completed in September 2011. The primary endpoint of the trial was successfully reached in March 2012. Apogenix was granted orphan drug designation for APG101 in 2009 for the treatment of GBM in Europe and in the US.

Contact
Dr Thomas Höger
CEO/CFO
Apogenix GmbH
Phone: +49 (6221) 5 86 08-0
Email: contact@apogenix.com
www.apogenix.com

Raimund Gabriel
MC Services AG
Phone: +49 (89) 210 228 30
Email: raimund.gabriel@mc-services.eu